Breaking News Instant updates and real-time market news.

GILD

Gilead

$79.12

1.26 (1.62%)

, GSK

GlaxoSmithKline

$43.13

0.23 (0.54%)

08:46
10/03/16
10/03
08:46
10/03/16
08:46

Gilead HIV franchise could see risk from competitor data, says RBC Capital

RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.

GILD

Gilead

$79.12

1.26 (1.62%)

GSK

GlaxoSmithKline

$43.13

0.23 (0.54%)

  • 06

    Nov

  • 11

    Nov

GILD Gilead
$79.12

1.26 (1.62%)

09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
GSK GlaxoSmithKline
$43.13

0.23 (0.54%)

08/29/16
PIPR
08/29/16
NO CHANGE
PIPR
Overweight
Gilead risk from possible 2-drug HIV regimens 'nothing new,' says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he has received a number of questions regarding a Wall Street Journal article highlighting a potential 2-drug HIV regimen based on GlaxoSmithKline's (GSK) dolutegravir, stating in response that 2-drug options looking to replace the 3-drug standard "have come and gone without success." Though there is "always the chance that a new 2-drug combo will thread the needle," Schimmer said he still strongly doubts the field will "rush to a novel paradigm any time soon" as he believes the advantage of a 2-drug over a 3-drug regimen is minimal. Gilead (GILD) is doing a "very good job converting it's HIV Viread-based regimens to TAF based ones" and should remain the leader in the HIV space when it can also offer an unboosted integrase inhibitor, said Schimmer, who keeps an Overweight rating on the stock.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Underperform
GlaxoSmithKline downgraded to Underperform from Neutral at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBI

First Midwest

$24.11

0.16 (0.67%)

18:01
04/25/17
04/25
18:01
04/25/17
18:01
Earnings
First Midwest reports Q1 adjusted EPS 34c, consensus 33c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 17

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:00
04/25/17
04/25
18:00
04/25/17
18:00
Hot Stocks
Breaking Hot Stocks news story on Frontline, DHT Holdings »

Frontline says makes new…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFLY

Shutterfly

$51.46

0.18 (0.35%)

17:58
04/25/17
04/25
17:58
04/25/17
17:58
Hot Stocks
Shutterfly to retire MyPublisher brand and cite in Q2 »

Comment from company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

HBNC

Horizon Bancorp

$27.24

0.37 (1.38%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Horizon Bancorp reports Q1 adjusted EPS 34c, consensus 41c »

Reports Q1 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:57
04/25/17
04/25
17:57
04/25/17
17:57
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

KMT

Kennametal

$40.48

1.15 (2.92%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Hot Stocks
Kennametal sees restructuring yielding annual pre-tax savings $165M-$180M »

"Restructuring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 30

    May

  • 31

    May

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:56
04/25/17
04/25
17:56
04/25/17
17:56
Earnings
Breaking Earnings news story on Boston Properties »

Boston Properties sees Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

BXP

Boston Properties

$133.97

1.18 (0.89%)

17:55
04/25/17
04/25
17:55
04/25/17
17:55
Earnings
Boston Properties reports Q1 EPS 63c, consensus 55c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

, IRBT

iRobot

$69.14

-0.12 (-0.17%)

17:54
04/25/17
04/25
17:54
04/25/17
17:54
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

IRBT

iRobot

$69.14

-0.12 (-0.17%)

EW

Edwards Lifesciences

$98.92

0.96 (0.98%)

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

JNPR

Juniper

$27.78

-0.49 (-1.73%)

CMG

Chipotle

$471.76

2.97 (0.63%)

ASYS

Amtech Systems

$5.50

-0.05 (-0.90%)

PETX

Aratana Therapeutics

$6.04

-0.07 (-1.15%)

DECK

Deckers Brands

$58.74

0.4 (0.69%)

COST

Costco

$172.68

0.35 (0.20%)

X

U.S. Steel

$31.11

-0.09 (-0.29%)

CREE

Cree

$24.82

0.07 (0.28%)

NUVA

NuVasive

$76.94

0.59 (0.77%)

DFS

Discover

$67.28

0.37 (0.55%)

ULTI

Ultimate Software

$210.91

0.99 (0.47%)

COF

Capital One

$85.58

0.9 (1.06%)

ILMN

Illumina

$181.50

1.3 (0.72%)

CHRW

C.H. Robinson

$77.70

0.11 (0.14%)

FLXN

Flexion

$25.96

-0.25 (-0.95%)

NBIX

Neurocrine

$53.62

1.84 (3.55%)

MPW

Medical Properties Trust

$13.84

0.03 (0.22%)

CCI

Crown Castle

$94.27

-0.44 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 15

    May

  • 18

    May

  • 18

    May

  • 25

    May

  • 31

    May

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 08

    Jun

  • 08

    Jun

  • 06

    Oct

  • 26

    Apr

  • 26

    Apr

SMBK

SmartFinancial

$22.31

0.61 (2.81%)

17:52
04/25/17
04/25
17:52
04/25/17
17:52
Earnings
SmartFinancial reports Q1 EPS 19c, two estimates 21c »

Reports Q1 NII $9.8M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SXT

Sensient

$83.27

1.18 (1.44%)

17:51
04/25/17
04/25
17:51
04/25/17
17:51
Earnings
Sensient reafirms FY17 adjusted EPS view $3.35-$3.45, consensus $3.41 »

Sensient updated FY17 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FTI

TechnipFMC

$32.12

0.23 (0.72%)

17:51
04/25/17
04/25
17:51
04/25/17
17:51
Hot Stocks
TechnipFMC awarded subsea contract for ExxonMobil Liza in Guyana »

Technip (FTI) has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

SXT

Sensient

$83.27

1.18 (1.44%)

17:50
04/25/17
04/25
17:50
04/25/17
17:50
Earnings
Sensient reports Q1 adjusted EPS 82c, consensus 82c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ZIXI

ZixCorp

$5.21

-0.14 (-2.62%)

17:41
04/25/17
04/25
17:41
04/25/17
17:41
Hot Stocks
ZixCorp announces up to $10M share repurchase program »

Zix Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

UMBF

UMB Financial

$77.08

0.195 (0.25%)

17:35
04/25/17
04/25
17:35
04/25/17
17:35
Hot Stocks
UMB Financial approves 2M shares repurchase plan »

UMB Financial approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 15

    May

MSA

MSA Safety

$73.25

0.9 (1.24%)

17:35
04/25/17
04/25
17:35
04/25/17
17:35
Earnings
MSA Safety reports Q1 cont ops EPS 37c, consensus 50c »

Reports Q1 revenue $266M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 11

    May

OESX

Orion Energy

$1.79

-0.04 (-2.19%)

17:32
04/25/17
04/25
17:32
04/25/17
17:32
Earnings
Orion Energy sees Q4 revenue $15.1-$15.5M, consensus $20.72M »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RCII

Rent-A-Center

$10.86

-0.15 (-1.36%)

17:29
04/25/17
04/25
17:29
04/25/17
17:29
Hot Stocks
Engaged Capital responds to Rent-A-Center »

Engaged Capital issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

LMT

Lockheed Martin

$270.02

-6.19 (-2.24%)

17:28
04/25/17
04/25
17:28
04/25/17
17:28
Hot Stocks
Lockheed Martin awarded $109.5M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.